【摘要】 目的观察并比较紫杉醇联合FOLFOX4方案与FOLFOX4方案治疗晚期胃癌的疗效及毒副反应。方法随机将晚期胃癌患者分为两组,A组32例,采用紫杉醇联合FOLFOX4方案化疗;B组31例,采用FOLFOX4方案化疗。每2周重复,28d为1周期,每例患者至少完成2周期以上的化疗。结果A组有效率(CR+PR)为43.7%,中位疾病进展时间5.87个月,中位生存期9.8个月;B组有效率(CR+PR)为35.5%,中位疾病进展时间3.9个月,中位生存期8.5个月。两组有效率差异无显著性(P>0.05),中位疾病进展时间及中位生存期差异均有显著性(P<0.05)。两组主要毒副反应为白细胞下降、脱发、肌肉关节痛,两组发生率比较差异具有显著性(P<0.05)。结论紫杉醇联合FOLFOX4方案治疗晚期胃癌具有良好的疗效和耐受性。更多还原

【Abstract】 Objective To compare the efficacy and toxicity of paclitaxel plus FOLFOX4 regimen and FOLFOX4 regimen in the treatment of patients with advanced gastric carcinoma(AGG).Methods A total of 63 patients with AGC were randomized into two groups.Two or more cycles of chemotherapy were completed.Group A consisted of 32 patients who received paclitaxel plus FOLFOX4 regimen and group B consisted of 31 patients who received FOLFOX4 regimen.Results The response rates(CR + PR) of groups A and B were 43.7% and 35.5% ,the median TTP was 5.87 and 3.9 months,and the median survival time of patients was 9.8 and 8.5 months,respectively.The response rates of the 2 groups had no significant difference(P > 0.05).The median TTP and the median survival time had significant difference(P <0.05).The major side effect of the two groups had significant difference(P < 0.05).Conclusion Paclitaxel plus FOLFOX4 regimen is an effective,acceptable and safe method for treatment of patients with advanced gastric cancer.更多还原